SNHG1

Summary

SNHG1 (small nucleolar RNA host gene 1, HGNC:32688) is a long non-coding RNA gene on chromosome 11q12.3.

This locus represents a small nucleolar RNA host gene that produces multiple alternatively spliced long non-coding RNAs. This gene is upregulated in cancers and is thought to act as promoter of cell proliferation. This transcript negatively regulates tumor suppressor genes such as tumor protein p53. Expression of this locus may be a marker of tumor progression.

Source: NCBI Gene 23642 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32688
Approved symbol	SNHG1
Name	small nucleolar RNA host gene 1
Location	11q12.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	UHG, NCRNA00057, LINC00057, lncRNA16
Ensembl gene	ENSG00000255717
Ensembl biotype	lncRNA
OMIM	603222
Entrez	23642
RNAcentral	URS0000CCE0E1 — lncRNA, 1137 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 363 — 350 lncRNA, 13 retained_intron

ENST00000535076, ENST00000535689, ENST00000537024, ENST00000537068, ENST00000537869, ENST00000537925, ENST00000537965, ENST00000538266, ENST00000538654, ENST00000539303, ENST00000539921, ENST00000539975, ENST00000540725, ENST00000540865, ENST00000540904, ENST00000541416, ENST00000541578, ENST00000541615, ENST00000542112, ENST00000544550, ENST00000544983, ENST00000545308, ENST00000545440, ENST00000545688, ENST00000545920, ENST00000652879, ENST00000653690, ENST00000655919, ENST00000656240, ENST00000656241, ENST00000656268, ENST00000656589, ENST00000658540, ENST00000660547, ENST00000660730, ENST00000660960, ENST00000661616, ENST00000661936, ENST00000662229, ENST00000662400, ENST00000663092, ENST00000663237, ENST00000663967, ENST00000664307, ENST00000665371, ENST00000665512, ENST00000667655, ENST00000668048, ENST00000668309, ENST00000670323, ENST00000670469, ENST00000670502, ENST00000670729, ENST00000671236, ENST00000685229, ENST00000685577, ENST00000686008, ENST00000686081, ENST00000686478, ENST00000686500, ENST00000686670, ENST00000686740, ENST00000687029, ENST00000687243, ENST00000688102, ENST00000689147, ENST00000689664, ENST00000690476, ENST00000690542, ENST00000691255, ENST00000691324, ENST00000692454, ENST00000692887, ENST00000693734, ENST00000700852, ENST00000701467, ENST00000702009, ENST00000702248, ENST00000702381, ENST00000702430, ENST00000742439, ENST00000742440, ENST00000742441, ENST00000742442, ENST00000742443, ENST00000742444, ENST00000742445, ENST00000742446, ENST00000742447, ENST00000742448, ENST00000742449, ENST00000742450, ENST00000742451, ENST00000742452, ENST00000742453, ENST00000742454, ENST00000742455, ENST00000742456, ENST00000742457, ENST00000742458, ENST00000742459, ENST00000742460, ENST00000742461, ENST00000742462, ENST00000742463, ENST00000742464, ENST00000742465, ENST00000742466, ENST00000742467, ENST00000742468, ENST00000742469, ENST00000742470, ENST00000742471, ENST00000742472, ENST00000742473, ENST00000742474, ENST00000742475, ENST00000742476, ENST00000742477, ENST00000742478, ENST00000742479, ENST00000742480, ENST00000742481, ENST00000742482, ENST00000742483, ENST00000742484, ENST00000742485, ENST00000742486, ENST00000742487, ENST00000742488, ENST00000742489, ENST00000742490, ENST00000742491, ENST00000742492, ENST00000742493, ENST00000742494, ENST00000742495, ENST00000742496, ENST00000742497, ENST00000742498, ENST00000742499, ENST00000742500, ENST00000742501, ENST00000742502, ENST00000742503, ENST00000742504, ENST00000742505, ENST00000742506, ENST00000742507, ENST00000742508, ENST00000742509, ENST00000742510, ENST00000742511, ENST00000742512, ENST00000742513, ENST00000742514, ENST00000742515, ENST00000742516, ENST00000742517, ENST00000742518, ENST00000742519, ENST00000742520, ENST00000742521, ENST00000742522, ENST00000742523, ENST00000742524, ENST00000742525, ENST00000742526, ENST00000742527, ENST00000742528, ENST00000742529, ENST00000742530, ENST00000742531, ENST00000742532, ENST00000742533, ENST00000742534, ENST00000742535, ENST00000742536, ENST00000742537, ENST00000742538, ENST00000742539, ENST00000742540, ENST00000742541, ENST00000742542, ENST00000742543, ENST00000742544, ENST00000742545, ENST00000742546, ENST00000742547, ENST00000742548, ENST00000742549, ENST00000742550, ENST00000742551, ENST00000742552, ENST00000742553, ENST00000742554, ENST00000742555, ENST00000742556, ENST00000742557, ENST00000742558, ENST00000742559, ENST00000742560, ENST00000742561, ENST00000742562, ENST00000742563, ENST00000742564, ENST00000742565, ENST00000742566, ENST00000742567, ENST00000742568, ENST00000742569, ENST00000742570, ENST00000742571, ENST00000742572, ENST00000742573, ENST00000742574, ENST00000742575, ENST00000742576, ENST00000742577, ENST00000742578, ENST00000742579, ENST00000742580, ENST00000742581, ENST00000742582, ENST00000742583, ENST00000742584, ENST00000742585, ENST00000742586, ENST00000742587, ENST00000742588, ENST00000742589, ENST00000742590, ENST00000742591, ENST00000742592, ENST00000742593, ENST00000742594, ENST00000742595, ENST00000742596, ENST00000742597, ENST00000742598, ENST00000742599, ENST00000742600, ENST00000742601, ENST00000742602, ENST00000742603, ENST00000742604, ENST00000742605, ENST00000742606, ENST00000742607, ENST00000742608, ENST00000742609, ENST00000742610, ENST00000742611, ENST00000742612, ENST00000742613, ENST00000742614, ENST00000742615, ENST00000742616, ENST00000742617, ENST00000742618, ENST00000742619, ENST00000742620, ENST00000742621, ENST00000742622, ENST00000742623, ENST00000742624, ENST00000742625, ENST00000742626, ENST00000742627, ENST00000742628, ENST00000742629, ENST00000742630, ENST00000742631, ENST00000742632, ENST00000742633, ENST00000742634, ENST00000742635, ENST00000742636, ENST00000742637, ENST00000742638, ENST00000742639, ENST00000742640, ENST00000742641, ENST00000742642, ENST00000742643, ENST00000742644, ENST00000742645, ENST00000742646, ENST00000742647, ENST00000742648, ENST00000742649, ENST00000742650, ENST00000742651, ENST00000742652, ENST00000742653, ENST00000742654, ENST00000742655, ENST00000742656, ENST00000742657, ENST00000742658, ENST00000742659, ENST00000742660, ENST00000742661, ENST00000742662, ENST00000742663, ENST00000742664, ENST00000742665, ENST00000742666, ENST00000742667, ENST00000742668, ENST00000742669, ENST00000742670, ENST00000742671, ENST00000742672, ENST00000742673, ENST00000742674, ENST00000742675, ENST00000742676, ENST00000742677, ENST00000742678, ENST00000742679, ENST00000742680, ENST00000742681, ENST00000742682, ENST00000742683, ENST00000742684, ENST00000742685, ENST00000742686, ENST00000742687, ENST00000742688, ENST00000742689, ENST00000742690, ENST00000742691, ENST00000742692, ENST00000742693, ENST00000742694, ENST00000742695, ENST00000742696, ENST00000742697, ENST00000742698, ENST00000742699, ENST00000742700, ENST00000742701, ENST00000742702, ENST00000742703, ENST00000742704, ENST00000742705, ENST00000742706, ENST00000742707, ENST00000742708, ENST00000742709, ENST00000742710, ENST00000742711, ENST00000742712, ENST00000742713, ENST00000742714, ENST00000742715, ENST00000742716, ENST00000742717, ENST00000742718, ENST00000742719, ENST00000742720, ENST00000742721

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000535076 — 5 exons

Exon	Start	End
ENSE00002226365	62855424	62855823
ENSE00002245839	62852005	62852681
ENSE00002272013	62853075	62853115
ENSE00002289729	62852811	62852839
ENSE00003881337	62853552	62855216

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 52.9562 / max 2280.4524, expressed in 1786 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120258	49.8517	1786
120255	2.8452	1030
120254	0.7072	341
120257	0.2269	83
120256	0.0325	11

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
colonic epithelium	UBERON:0000397	98.42	gold quality
left ovary	UBERON:0002119	98.41	gold quality
ganglionic eminence	UBERON:0004023	98.26	gold quality
lower esophagus mucosa	UBERON:0035834	98.23	gold quality
ovary	UBERON:0000992	98.22	gold quality
right uterine tube	UBERON:0001302	98.18	gold quality
sural nerve	UBERON:0015488	98.17	gold quality
right ovary	UBERON:0002118	98.10	gold quality
ventricular zone	UBERON:0003053	97.95	gold quality
bone marrow	UBERON:0002371	97.73	gold quality
body of pancreas	UBERON:0001150	97.67	gold quality
lymph node	UBERON:0000029	97.60	gold quality
granulocyte	CL:0000094	97.53	gold quality
cerebellar hemisphere	UBERON:0002245	97.29	gold quality
cortical plate	UBERON:0005343	97.29	gold quality
cerebellar cortex	UBERON:0002129	97.28	gold quality
spleen	UBERON:0002106	97.27	gold quality
cerebellum	UBERON:0002037	97.23	gold quality
bone marrow cell	CL:0002092	97.21	gold quality
skin of abdomen	UBERON:0001416	97.16	gold quality
esophagus mucosa	UBERON:0002469	97.12	gold quality
zone of skin	UBERON:0000014	96.99	gold quality
vagina	UBERON:0000996	96.97	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.95	gold quality
skin of leg	UBERON:0001511	96.90	gold quality
ectocervix	UBERON:0012249	96.71	gold quality
uterine cervix	UBERON:0000002	96.66	gold quality
endocervix	UBERON:0000458	96.65	gold quality
body of uterus	UBERON:0009853	96.55	gold quality
fallopian tube	UBERON:0003889	96.49	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.47

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• High small nucleolar RNA host gene 1 expression is associated with nonsmall cell lung cancer. (PMID:25818744)
• Study shows that a group of polycistronic miRNA-like non-coding RNAs derived from small nucleolar RNAs (sno-miRNAs) are transcriptionally repressed by p53 through their host gene, SNHG1. The most abundant of these, sno-miR-28, directly targets the p53-stabilizing gene, TAF9B. (PMID:26061048)
• SNHG1 promotes Hepatocellular carcinoma cells proliferation through inhibiting p53 and p53-target genes expression. (PMID:27133041)
• SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk neuroblastoma intervention. (PMID:27517149)
• lncRNA16 promotes G2/M transition by regulating cyclin B1 transcription in lung tumor cells, promoting tumor cell proliferation. (PMID:27999202)
• lncRNA SNHG1 could promote non-small cell lung cancer progression via miR-101-3p and SOX9. (PMID:28147312)
• Our results indicate that a balance between lncRNA SNHG1 and hnRNPC regulates p53 activity and p53-dependent apoptosis upon doxorubicin treatment, and further indicate that a change in lncRNA subcellular localization under specific circumstances is biologically significant. (PMID:28264987)
• Taken together, these findings elucidated a novel mechanism of prostate cancer progression. Thus, SNHG1 might serve as a potential target for prostate cancer therapies. (PMID:28400279)
• SNHG1 might play an oncogenic role in SCC through ZEB1 signaling pathway by inhibiting TAp63. (PMID:28415044)
• lncRNA-Snhg1 promoted cell proliferation by acting as a non-degradable sponge for the tumor suppressor miR-338 in esophageal cancer cells. (PMID:28423738)
• ectopic expression of SNHG1 enhanced cell proliferation and cell invasion and reduced cell apoptosis. (PMID:28501778)
• The LncRNA SNHG1 promotes DNMT1 expression, which facilitates the gastric cancer proliferation. (PMID:28754593)
• Down-regulated long non-coding RNA SNHG1 results in smaller tumor size and lighter tumor weight, suggening SNHG1 might act as an important potential therapeutic target in CRC treatment. (PMID:28759957)
• Findings indicate that long noncoding RNAs (lncRNAs) SNHG1 can function both in cis and in trans with distinct mechanisms to regulate transcription, promoting tumorigenesis and cancer progression. (PMID:28825722)
• Results indicate that lncRNA SNHG1 may be a potential predictor of prognosis in esophageal squamous cell cancer (ESCC) patients, and that knockdown of SNHG1 suppressed the Notch signaling pathway by reducing the Notch1 expression levels in ESCC cells. (PMID:29081407)
• Lnc-SNHG1 was highly expressed in osteosarcoma tissues and cells. (PMID:29108989)
• Authors identified that SNHG1 increased human nin one binding protein (NOB1), an oncogene, through sponging miR-326 as competing endogenous RNA (ceRNA), finally prompting cell growth, migration and invasion in OS. (PMID:29115574)
• Data suggest that lncRNA small nucleolar RNA host gene 1, as a pathogenic factor, promotes alpha-synuclein aggregation and toxicity by targeting the miR-15b-5p/seven in absentia homolog 1 axis. (PMID:29217406)
• Our study provides strong evidence that SNHG1 may significantly be associated with the development and progression of colorectal cancer (PMID:29441936)
• SNHG1 contributes to NSCLC progression by modulating the miR-145-5p/MTDH axis. (PMID:29466052)
• Ectopic expression of SNHG1 inhibited miR-326 expression in nucleus pulposus cells and promoted CCND1 expression. (PMID:29466672)
• the impaired cell migration and invasion by SNHG1 siRNA could be rescued by cotransfection of miR-145-5p in CNE and HNE-1 cells. LncRNA SNHG1 promoted the expression of NUAK1 by down-regulating miR-145-5p and thus promoted the aggressiveness of nasopharyngeal carcinoma cells through AKT signalling pathway and induced epithelial-mesenchymal transition (EMT). (PMID:29575772)
• Our results indicated that SNHG1 and its interrelated components may be future therapeutic targets of carcinoma of the colon. (PMID:29749530)
• High levels of SNHG1 were correlated with poor prognosis of RCC patients. Knockdown of SNHG1 suppressed the proliferation, invasion, and EMT capacity in RCC. Moreover, miR-137 abrogated the effect of SNHG1 on RCC. (PMID:29874202)
• Upregulated long noncoding RNA Snhg1 promotes the angiogenesis of brain microvascular endothelial cells after oxygen-glucose deprivation treatment by targeting miR-199a (PMID:29883549)
• Interference SNHG1 could inhibit the differentiation of Treg cells by promoting miR-448 expression and reducing IDO level, thereby impeding the immune escape of breast cancer . (PMID:29886172)
• plasma SNHG1 was significantly higher in patients with HCC compared with expression levels in patients with HCH or healthy individuals. Increased plasma SNHG1 expression may be a valuable biomarker for HCC diagnosis. (PMID:30066898)
• Systematic literature review and meta-analysis identified eight publications that included 570 patients with eight types of solid malignant tumor, and showed that the expression of the lncRNA SNHG1 was significantly associated with worse clinical outcome (PMID:30080819)
• SNHG1 represents promising novel biomarkers for various cancer types and have a great potential to be effectively used in clinical practice in the near future. (PMID:30107989)
• the results of our studies illuminate how SNHG1 formed a regulatory network to confer an oncogenic function in colorectal cancer and suggest that SNHG1 may serve as a potential target for colorectal cancer diagnosis and treatment. (PMID:30266084)
• The effects of SNHG1 overexpression attenuated the H2O2-inudced increased in the protein levels of cleaved caspase-3, cleaved caspase-9 and Bax in the human cardiomyocytes. (PMID:30355909)
• SNHG1 promoted GC cell proliferation and invasion via modulating the miR-140/ADAM10 axis (PMID:30391432)
• lnc-SNHG1 regulated the expression of the insulin-like growth factor 1 receptor (IGF1-R) by acting as a sponge of miR-497 in non-small cell lung cancer. (PMID:30454699)
• identified MATR3 as binding to SNHG1 and the interaction might be involved in splicing events that enhance neuroblastoma progression. (PMID:30516047)
• the lncRNA SNHG1 acted as an oncogene in OS cancer; it downregulated the expression of miRNA-101-3p and promoted cancer cell proliferation, migration and invasion through activating the expression of ROCK1, the PI3K/AKT pathway and EMT. (PMID:30592267)
• this study demonstrates that the SNHG1- microRNA-154-5p/miR-376b-3p- FOXP2- KDM5B feedback loop plays a pivotal role in regulating the malignant behavior of glioma cells. (PMID:30728054)
• our study first uncovered that SNHG1 functioned as an oncogenic lncRNA that enhanced tumorigenesis and progression of CCA through the miR-140/TLR4/NF-kappaB signaling axis. Our findings suggested that SNHG1 might act as a therapeutic target as well as a diagnostic and prognostic marker for CCA. (PMID:30764893)
• REVIEW: Upregulation of SNHG1 was significantly associated with advanced tumour stage, tumour size, TNM stage and decreased overall survival. Furthermore, aberrant expression of SNHG1 contributes to cell proliferation, metastasis, migration and invasion of cancer cells. (PMID:30849309)
• LncRNA SNHG1 promotes liver cancer development through inhibiting p53 expression via binding to DNMT1. (PMID:31002127)
• Increased expression significantly associated with lymph node metastasis [meta-analysis] (PMID:31008944)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.